ADC Therapeutics SA — Form 6-K Summary
Business context and reporting period
ADC Therapeutics SA, a Swiss biotechnology company and foreign private issuer, filed Form 6-K in November 2021. The referenced reporting period covers the three and nine months ended September 30, 2021. The filing identifies unaudited IFRS condensed consolidated interim financial statements and related management discussion and analysis as Exhibits 99.1 and 99.2.
Financial metrics
The provided filing text contains only the Form 6-K cover page and exhibit index. It does not provide clear values for revenue, profit or loss, cash flow, margins, debt, liquidity, cash balances, or other financial metrics.
Material changes versus the prior comparable period
The provided text does not include the financial statements or management discussion required to assess changes versus the prior comparable period.
Guidance, outlook, risks, contingencies, and unusual items
The provided text does not contain guidance, outlook commentary, risk disclosures, contingencies, or unusual-item details. Exhibit 99.3 is identified as a press release dated November 2, 2021, but its contents are not included.
Important facts for investors to verify
- Review Exhibit 99.1 for the September 30, 2021 IFRS financial statements, cash position, operating results, and liquidity.
- Review Exhibit 99.2 for management’s discussion of period-over-period changes, financing needs, commitments, and risks.
- Review Exhibit 99.3 for any contemporaneous business updates, guidance, or clinical and regulatory developments.
- Note that the report, other than Exhibit 99.3, was incorporated by reference into specified Form F-3 registration statements.